Humacyte (HUMA) Company Report

Humacyte reported Q3 2025 revenue of $0.8 million, including $0.7 million from U.S. Symvess sales, a substantial increase from $100,000 in the previous quarter.
Commercial traction for Symvess includes 25 Value Analysis Committee (VAC) approvals covering 92 civilian hospitals and the first commercial sale to U.S. military facilities after ECAT approval.
The company's net loss decreased to $17.5 million for Q3 2025, down from $39.2 million in the prior year, primarily due to a non-cash remeasurement of contingent earnout liability and reduced operating expenses.
Humacyte is on track for $50 million in cost savings for 2025-2026, with current cash expected to provide a runway beyond 12 months, covering key milestones such as the planned H2 2026 BLA filing for dialysis access.
The company has opted not to resubmit for NTAP in trauma, noting that price reductions have accelerated market activity and that only a small percentage of trauma patients are covered by Medicare.

Nov 12, 2025, 1:00 PM

Transcript

Humacyte Reports Q3 2025 Financial Results and Commercial Progress

HUMA

Earnings

Product Launch

New Projects/Investments

Humacyte reported Q3 2025 revenue of $0.8 million, including $0.7 million from U.S. Symvess sales, a substantial increase from $100,000 in the prior quarter.
The company secured 25 Value Analysis Committee (VAC) approvals, making Symvess available to 92 civilian hospitals, with 45 additional VAC committees currently reviewing the product.
Net loss for Q3 2025 improved to $17.5 million, down from $39.2 million in the prior year, partially due to non-cash remeasurement and reduced operating expenses.
Humacyte is on track to achieve $50 million in cost savings for 2025-2026, with Q3 research and development expenses decreasing by $5 million quarter-over-quarter.
The company's $76 million cash balance is projected to fund operations beyond 12 months, supporting milestones such as the BLA filing for dialysis access in H2 2026 and first-in-human CABG studies in 2026.

Nov 12, 2025, 1:00 PM

Transcript

Humacyte Reports Q3 2025 Financial Results and Symvess Commercial Progress

HUMA

Earnings

Product Launch

Guidance Update

Humacyte (HUMA) reported Q3 2025 revenue of $0.8 million, with $0.7 million attributed to U.S. sales of Symvess, a significant increase from $0.1 million in the previous quarter. For the nine months ended September 30, 2025, total revenue was $1.6 million.
The company's net loss for Q3 2025 was $17.5 million, a reduction from a net loss of $39.2 million in the prior year period, primarily due to a non-cash remeasurement of contingent earnout liability and decreased operating expenses.
The commercial launch of Symvess continues to advance, with 25 hospitals and/or healthcare systems having completed the Value Analysis Committee (VAC) process and approved its purchase, representing 92 civilian hospitals eligible to buy Symvess. An additional 45 VAC committees are currently reviewing Symvess. The majority of hospitals that have started ordering Symvess have also reordered.
As of September 30, 2025, Humacyte held $19.8 million in cash, cash equivalents, and restricted cash. Subsequent to this date, the company secured an additional $56.5 million in net proceeds from the sale of common stock and warrants, which is expected to provide a cash runway exceeding 12 months from November 12, 2025. The company is also on track to achieve $50 million in targeted cost savings for 2025 and 2026.

Nov 12, 2025, 1:00 PM

Transcript

Humacyte Announces Third Quarter 2025 Financial Results and Business Update

HUMA

Earnings

Product Launch

New Projects/Investments

Humacyte reported total revenues of $753,000 for the third quarter of 2025, with Symvess sales reaching $703,000, a substantial increase from $100,000 in the second quarter.
The company's net loss for Q3 2025 was $17.5 million, a decrease from $39.2 million in the prior year period.
As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $19.8 million.
Symvess market access expanded to 92 civilian hospitals through 25 Value Analysis Committee (VAC) approvals.
Humacyte advanced its pipeline with positive two-year results for the ATEV in dialysis from the V007 Phase 3 trial and submitted an Investigational New Drug (IND) application for the Coronary Tissue Engineered Vessel (CTEV) in the CABG indication, with plans for a first-in-human study in 2026.

Nov 12, 2025, 12:06 PM

8-K

Humata Health Partners with CMS for WISeR Model

HUMA

New Projects/Investments

Product Launch

Humata Health has been selected by the Centers for Medicare & Medicaid (CMS) as a key partner for its WISeR model, an initiative to make clinical approvals faster, fairer, and more efficient using AI-powered prior authorization technology.
The WISeR model will launch in January 2026 in six states, with Humata Health serving as the primary technology partner for Oklahoma to process prior authorization requests for a specific list of 17 items and services.
Humata's AI technology is designed to accelerate approvals by matching clinical documentation to Medicare policy criteria, delivering rapid automated "yes" decisions, and has previously demonstrated improvements in authorization cycle times by over 50% and reductions in preventable denials by up to 40%.

Nov 7, 2025, 3:00 PM

Press Release

Humacyte to Release Third Quarter 2025 Financial Results and Provide Business Update

HUMA

Earnings

Product Launch

Humacyte, Inc. (Nasdaq: HUMA) is scheduled to release its third quarter 2025 financial results for the period ended September 30, 2025, on November 12, 2025.
Management will host a webcast and conference call at 8:00 a.m. ET on November 12, 2025, to provide a corporate and financial update.
The company's Biologics License Application for its acellular tissue engineered vessel (ATEV) in the vascular trauma indication received FDA approval in December 2024.

Nov 6, 2025, 1:00 PM

Press Release

Humacyte announces pricing of $60.0 million registered direct offering

HUMA

Humacyte, Inc. announced the pricing of an oversubscribed registered direct offering, expecting to generate approximately $60.0 million in gross proceeds before fees and expenses.
The offering involves the sale of 28,436,018 shares of common stock and warrants to purchase an equal number of shares.
The purchase price for one share of common stock and one warrant is $2.11.
The warrants will become exercisable 180 days following issuance, have an exercise price of $2.11 per share, and will expire on April 7, 2031.
The offering is expected to close on or about October 8, 2025.

Oct 7, 2025, 9:31 PM

8-K

Humacyte Announces Positive Long-Term Results for Symvess in Wartime Trauma

HUMA

Product Launch

New Projects/Investments

Humacyte announced the publication of positive long-term results for its Symvess product, used to treat wartime vascular trauma injuries in Ukraine.
The study, published in Military Medicine, reported a continued high rate of patency (87.1%), 100% limb salvage, and zero cases of conduit infection in 17 patients followed for up to 18 months.
Patients treated with Symvess experienced zero deaths, zero amputations, and zero infections at both 30 days and up to 18 months of follow-up.
Symvess, an acellular tissue engineered vessel, is designed for immediate off-the-shelf availability, which is critical for wartime situations.
The FDA approved Humacyte's Biologics License Application for ATEV in the vascular trauma indication in December 2024.

Oct 6, 2025, 12:00 PM

Press Release

Humacyte Amends Revenue Interest Purchase Agreement, Repays Debt

HUMA

Debt Issuance

Humacyte, Inc. (HUMA) and its subsidiary, Humacyte Global, Inc., entered into Amendment No. 2 to the Revenue Interest Purchase Agreement on September 17, 2025.
The company will make a $50.0 million repayment under the Purchase Agreement, funded from existing restricted cash.
This amendment removes the obligation to maintain $50.0 million of restricted cash, unless the Purchase Agreement is not fully repaid by December 31, 2025, in which case $12.5 million will be required.
Humacyte now has the option to exercise its call option at a discounted repurchase price of $95.5 million if exercised on or prior to December 31, 2025.
Up to $7.5 million of this call option may be satisfied through the issuance of the company's common stock.

Sep 18, 2025, 1:45 AM

8-K

Earnings Transcripts

Quarterly earnings call transcripts for Humacyte.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Laura E. Niklason say about margins?What are Humacyte's strategic priorities?How is Humacyte positioned vs competitors?How did Humacyte do last quarter?

Let Fintool AI Agent track Humacyte's earnings for you

Get instant analysis when filings drop